Bonesupport Holding AB

BONEX

SE0009858152

Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 08:59:36 28/05/2024 pm IST			5-day change	1st Jan Change
248.8 ^SEK	-3.72%		+1.80%	+32.20%

25/04	Transcript : Bonesupport Holding AB, Q1 2024 Earnings Call, Apr 25, 2024
25/04	Bonesupport Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Bonesupport Holding AB Elects Simon Cartmell as New Ordinary Board Member

May 22, 2018 at 04:30 pm IST

Bonesupport Holding AB announced that at the annual shareholders meeting held on 22 May 2018 approved to elect Simon Cartmell as new ordinary board member.

Latest news about Bonesupport Holding AB

Transcript : Bonesupport Holding AB, Q1 2024 Earnings Call, Apr 25, 2024	25/04
Bonesupport Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04	CI
Nordic Shares Decreased Friday; BoneSupport Holding Posted Biggest Loss	15/03	DJ
Nordic Stocks Moved Upward Thursday; Scatec Climbed Highest	14/03	DJ
Bonesupport’s Orthopedic Medical Device for Open Fractures Gains US FDA Nod	14/03	MT
Nordic Shares Moved Upward Wednesday; BoneSupport Holding Topped Leaders	06/03	DJ
Bonesupport Holding AB Announces Resignation of Kristina Ingvar as Executive Vice President Quality Management & Regulatory Affairs	23/02	CI
Nordic Stocks Closed Up Monday; Tele2 Series a Topped Leaders	19/02	DJ
Nordic Stocks Closed Up Friday; Yubico Led Increases	16/02	DJ
Bonesupport Holding AB Reports Earnings Results for the Full Year Ended December 31, 2023	16/02	CI
Bonesupport Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	16/02	CI
Transcript : Bonesupport Holding AB, 2023 Earnings Call, Feb 15, 2024	15/02
Transcript : Bonesupport Holding AB - Analyst/Investor Day	28/11
Bonesupport Holding AB Provides Sales Guidance for the Year 2024	28/11	CI
Bonesupport Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	27/23/27	CI
Transcript : Bonesupport Holding AB, Nine Months 2023 Earnings Call, Oct 26, 2023	26/23/26
Bone Support Receives ?Breakthrough Device Designation? for Cerament® V for the Indication of Bone Infection	16/23/16	CI
Transcript : Bonesupport Holding AB, Q2 2023 Earnings Call, Jul 13, 2023	13/23/13
Bonesupport Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	13/23/13	CI
Bonesupport Holding AB Launches Next Generation of CeramentÂ® G	29/23/29	CI
BONESUPPORT Holding AB Announces Strong Long-Term Results with CERAMENT®G for Severe Open Fractures	25/23/25	CI
Transcript : Bonesupport Holding AB, Q1 2023 Earnings Call, Apr 27, 2023	27/23/27
Bonesupport Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2023	27/23/27	CI
Transcript : Bonesupport Holding AB, 2022 Earnings Call, Feb 16, 2023	16/23/16
Bonesupport Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	16/23/16	CI

Bonesupport Holding AB is a Sweden-based orthobiologics company. It develops and commercialize injectable bioceramic bone graft substitutes which remodel to host bone and have the capability to elute drugs directly into the bone void. The marketed synthetic bone graft substitutes are CERAMENT BVF, CERAMENT G and CERAMENT V, which are based on the CERAMENT technology platform. The products are commercially available in Europe and the United States, as well as in India, Malaysia, Oman and Singapore. The products are developed to treat patients with fractures and bone voids caused by trauma and related surgery, as well as caused by infection or diseases, such as chronic osteomyelitis, revision arthroplasty and infected diabetic foot.

Sector

Pharmaceuticals

Calendar

11/07/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Bonesupport Holding AB

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

248.8 SEK

Average target price

292.7 SEK

Spread / Average Target

+17.63%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
BONESUPPORT HOLDING AB	+32.20%	1.6B
CSL LIMITED	-1.64%	90.28B
SAMSUNG BIOLOGICS CO.,LTD.	-1.97%	39.5B
BIOGEN INC.	-15.47%	31.71B
UCB	+61.28%	26.41B
BIOMARIN PHARMACEUTICAL INC.	-22.81%	14.34B
INCYTE CORPORATION	-8.82%	12.89B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.77%	11.8B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-45.97%	10.95B
SWEDISH ORPHAN BIOVITRUM AB	+3.30%	8.85B

Biopharmaceuticals